# Forte Biosciences Inc. (FBRX) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $76.99, market value $1.6 billion.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Forte Biosciences Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / sales: 45400.8×**. Each dollar of revenue is priced at 45400.8×, a level that requires very high margins or very fast growth to justify.
- **Price / book: 10.2×**. The shares trade at 10.2× book value; most of the value is in earnings power and intangibles rather than the balance sheet.
- **Free-cash-flow yield: -4.4%**. Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Return on equity: -113.7%**. Return on equity is negative because earnings are negative.
- **Return on invested capital: -39.7%**. Return on all capital, debt included, is -39.7%: close to or below the cost of capital, so growth may not create value.
- **Return on assets: -4.9%**. Each dollar of assets produces -4.9% of profit.

## Growth
- **EPS growth (1 yr): 61.3%**. Earnings per share rose 61.3%.

## Financial health
- **Debt to equity: 0.43**. Debt is 0.43 times equity: a conservative balance sheet.
- **Net debt / EBITDA: 12.5×**. It would take 12.5 years of operating earnings to repay net borrowings, above the 3× level most lenders treat as comfortable.
- **Interest coverage: -1.1×**. Operating profit covers interest only -1.1×: fragile.
- **Current ratio: 3.88** (quick 3.88). Current assets cover the next year's liabilities 3.88 times.
- **Piotroski F-score: 2/9**. 2 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Forte Biosciences Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: buy** (4 analysts). 4 analysts cover Forte Biosciences Inc.; the consensus is buy, with an average price target of $73.00 (-5% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 583.7%** (YTD 182.3%, 3-mo 258.6%). The shares are up 583.7% over twelve months including dividends.
- **From 52-week high: -0.3%** (661.5% above the low). Trading within 5% of its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 84**. An RSI of 84 is in overbought territory; short-term pullbacks are common from here.
- **Beta (1 yr): 0.94** (volatility 130%). Beta of 0.94 against the S&P 500: the shares move roughly with the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=FBRX · Page: https://foliofundamentals.com/stocks/fbrx

Not investment advice.